Annual Operating Expenses
$252.10 M
+$116.23 M+85.54%
December 31, 2023
Summary
- As of February 7, 2025, NMRA annual total operating expenses is $252.10 million, with the most recent change of +$116.23 million (+85.54%) on December 31, 2023.
- During the last 3 years, NMRA annual operating expenses has risen by +$156.58 million (+163.93%).
- NMRA annual operating expenses is now at all-time high.
Performance
NMRA Operating Expenses Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Operating Expenses
$76.65 M
+$12.82 M+20.09%
September 30, 2024
Summary
- As of February 7, 2025, NMRA quarterly total operating expenses is $76.65 million, with the most recent change of +$12.82 million (+20.09%) on September 30, 2024.
- Over the past year, NMRA quarterly operating expenses has increased by +$16.57 million (+27.59%).
- NMRA quarterly operating expenses is now -56.97% below its all-time high of $178.13 million, reached on September 1, 2021.
Performance
NMRA Quarterly Operating Expenses Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Operating Expenses Formula
Operating Expenses = Selling, General & Administrative (SG&A) Expenses + Research & Development (R&D) Expenses + Depreciation & Amortization + Other Operating Expenses
NMRA Operating Expenses Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +85.5% | +27.6% |
| 3 y3 years | +163.9% | +144.8% |
| 5 y5 years | - | +144.8% |
NMRA Operating Expenses Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | at high | +85.5% | -32.8% | +188.7% |
| 5 y | 5-year | at high | +163.9% | -57.0% | +396.3% |
| alltime | all time | at high | +163.9% | -57.0% | +396.3% |
Neumora Therapeutics Operating Expenses History
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2024 | - | $76.65 M(+20.1%) |
| Jun 2024 | - | $63.82 M(+6.2%) |
| Mar 2024 | - | $60.07 M(-47.3%) |
| Dec 2023 | $252.10 M(+85.5%) | $114.00 M(+100.5%) |
| Sep 2023 | - | $56.86 M(+35.2%) |
| Jun 2023 | - | $42.06 M(+7.4%) |
| Mar 2023 | - | $39.17 M(+27.5%) |
| Dec 2022 | $135.87 M | $30.72 M(+0.4%) |
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2022 | - | $30.60 M(-2.3%) |
| Jun 2022 | - | $31.31 M(-27.6%) |
| Mar 2022 | - | $43.24 M(+62.9%) |
| Dec 2021 | $237.32 M(+148.5%) | - |
| Dec 2021 | - | $26.55 M(-85.1%) |
| Sep 2021 | - | $178.13 M(+935.6%) |
| Jun 2021 | - | $17.20 M(+11.4%) |
| Mar 2021 | - | $15.45 M(-20.9%) |
| Dec 2020 | $95.52 M | $19.53 M |
FAQ
- What is Neumora Therapeutics annual total operating expenses?
- What is the all time high annual operating expenses for Neumora Therapeutics?
- What is Neumora Therapeutics annual operating expenses year-on-year change?
- What is Neumora Therapeutics quarterly total operating expenses?
- What is the all time high quarterly operating expenses for Neumora Therapeutics?
- What is Neumora Therapeutics quarterly operating expenses year-on-year change?
What is Neumora Therapeutics annual total operating expenses?
The current annual operating expenses of NMRA is $252.10 M
What is the all time high annual operating expenses for Neumora Therapeutics?
Neumora Therapeutics all-time high annual total operating expenses is $252.10 M
What is Neumora Therapeutics annual operating expenses year-on-year change?
Over the past year, NMRA annual total operating expenses has changed by +$116.23 M (+85.54%)
What is Neumora Therapeutics quarterly total operating expenses?
The current quarterly operating expenses of NMRA is $76.65 M
What is the all time high quarterly operating expenses for Neumora Therapeutics?
Neumora Therapeutics all-time high quarterly total operating expenses is $178.13 M
What is Neumora Therapeutics quarterly operating expenses year-on-year change?
Over the past year, NMRA quarterly total operating expenses has changed by +$16.57 M (+27.59%)